Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna.

Plus, news about Atara Bio­ther­a­peu­tics, Im­mutep, blue­bird bio, OSE Im­munother­a­peu­tics, Mer­sana Ther­a­peu­tics, ...

Aldeyra Therapeutics reports Phase 3 success with reproxalap for dry eye disease, plans third FDA filing after previous ...

A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...

Bristol Myers Squibb is letting go of 516 workers in New Jersey as part of a wide-reaching cost-cutting plan aimed at making ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...